ClinicalTrials.gg
Enrolling by invitationNCT07395219EURO-TIFUpdated Feb 9, 2026

European TIF2.0 Registry

An observational study in Gastro -Oesophagal Reflux and Laryngo-pharyngeal Reflux, sponsored by Cleveland Clinic London. Enrolling by invitation at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Cleveland Clinic London · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Gastroesophageal Reflux with a site in Austria — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Austria.

Started
2023
the only one that year
Observational
8 of 26
1 open now
Registered
26th of 26
by date
Lead sponsor
1 of 26
Cleveland Clinic London

Among the 26 studies in Gastroesophageal Reflux with a site in Austria, this one is the only one that started in 2023, is one of 8 observational ones, and was the 26th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

2 of the 26 studies in Gastroesophageal Reflux with a site in Austria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Gastroesophageal Reflux with a site in Austria, or all of them as a file.
02

Study summary

This is a European, multi-centre, prospective registry that aims to determine the safety and efficacy of transoral incisionless fundoplication, with or without concomitant hiatal hernia repair, for the treatment of patients with gastro-oesophageal reflux disease (GORD).

03

Conditions studied

  • Gastro -Oesophagal Reflux
  • Laryngo-pharyngeal Reflux

Keywords

  • TIF
  • cTIF
  • GORD
  • GERD
  • Endoscopic intervention
  • Endoscopy
  • reflux
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with gastro-oesophageal reflux disease or laryngo-pharyngeal reflux undergoing transoral incisionless fundoplication with or without concomitant hiatal hernia repair

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any adult patient (≥18 years old) undergoing TIF2.0 or cTIF, at a participating centre, who can understand and sign the form, and is conducted in line with local institutional review board approval and recommendations.

Exclusion criteria

Exclusion Criteria:

  • There are no specific exclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes

Groups and cohorts

  • Patients with gastro-oesophageal reflux disease or laryngo-pharyngeal reflux

    Device: Transoral incisionless fundoplication with or without concomitant hiatal hernia repair with the EsophyX device

Interventions

  • DeviceTransoral incisionless fundoplication with or without concomitant hiatal hernia repair with the EsophyX device

    Transoral Incisionless Fundoplication (TIF): The TIF procedure is an endoscopic, minimally invasive intervention designed to reconstruct the gastro-oesophageal valve and restore its function as a reflux barrier, without external incisions. The procedure is performed transorally using the EsophyX device under general anaesthesia. The device enables the creation of a 270° to 300° esophagogastric fundoplication. Concomitant TIF (cTIF): The cTIF procedure combines a laparoscopic hiatal hernia repair with the TIF performed in the same session. Patients with a hiatal hernia greater than 2 cm undergo laparoscopic reduction and crural repair, followed immediately by the TIF procedure using the EsophyX device. This combined approach addresses both the anatomical defect of the hiatal hernia and the functional deficiency of the gastro-oesophageal valve.

    Also known as: TIF, cTIF

06

What researchers measure

Primary outcomes

  1. Gastroesophageal reflux disease health-related quality of life questionnaire (GERD-HRQL)

    Change in reflux-specific quality of life questionnaires (The GERD-HRQL used in the study is composed of 16 questions related to symptoms of heartburn, regurgitation, swallowing and overall satisfaction. Each question provides a scaled score between 0-5 (0=no symptoms, 5= Symptoms incapacitating to do daily activities) with a total score of 75.)

    Time frame: 6-months, 1-year, 2-year, 3-years, 5-, years

  2. Reflux symptom index (RSI)

    Change in reflux-specific quality of life questionnaire (The RSI used in the study is composed of 9 questions related to atypical symptoms of reflux or 'LPR'. Each question provides a scaled score between 0-5 (0=no problems, 5=severe problems) with a total score of 45.)

    Time frame: 6-months, 1-year, 2-years, 3-years, 5-years

  3. Proton pump inhibitor and/or histamine-2 receptor antagonist use

    Change in acid suppression use

    Time frame: 6-months, 1-year, 2-years, 3-years, 5-years

Secondary outcomes

  1. Physiological reflux testing

    Change in pH physiological testing

    Time frame: up to 5-years

  2. Procedural outcomes (technical success)

    Defined as successful completion of all steps of the cTIF or TIF2.0 procedure in the same sitting

    Time frame: 30-days

  3. Procedural outcomes (duration)

    Total length of the procedure in minutes

    Time frame: 30-days

  4. Procedural outcomes (length of hospital stay

    The time in days from procedure to discharge from hospital

    Time frame: 30-days

  5. Adverse events

    Adverse events (AE) following TIF2.0 according to the AGREE classification

    Time frame: up to 30-days

  6. Adverse events of special interest

    Subjective reporting of dysphagia, excessive belching or inability to belch, significant bloating and/or distension, and persistent nausea and vomiting.

    Time frame: Up to 5-years

  7. Need for revisional procedure

    The need for repreat endoscopic or surgical intervention due to recurrence of symptoms, failure of procedure of adverse events

    Time frame: Up to 5-years

07

Study locations

7 sites
08

References and documents

Publications

  • Testoni S, Hassan C, Mazzoleni G, Antonelli G, Fanti L, Passaretti S, Correale L, Cavestro GM, Testoni PA. Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: systematic-review and meta-analysis. Endosc Int Open. 2021 Feb;9(2):E239-E246. doi: 10.1055/a-1322-2209. Epub 2021 Feb 3. PubMed 33553587 ↗
  • Demartini B, Nistico V, D'Agostino A, Priori A, Gambini O. Early Psychiatric Impact of COVID-19 Pandemic on the General Population and Healthcare Workers in Italy: A Preliminary Study. Front Psychiatry. 2020 Dec 22;11:561345. doi: 10.3389/fpsyt.2020.561345. eCollection 2020. PubMed 33414728 ↗
  • Cristol DA, Evers DC. The impact of mercury on North American songbirds: effects, trends, and predictive factors. Ecotoxicology. 2020 Oct;29(8):1107-1116. doi: 10.1007/s10646-020-02280-7. Epub 2020 Sep 24. PubMed 32970279 ↗
  • Rahimi Z, Ghorbani-Shahna F, Bahrami A. Design, Implementation, and Evaluation of Industrial Ventilation Systems and Filtration for Silica Dust Emissions from a Mineral Processing Company. Indian J Occup Environ Med. 2021 Oct-Dec;25(4):192-197. doi: 10.4103/ijoem.IJOEM_55_19. Epub 2021 Dec 31. PubMed 35197669 ↗
  • Globig P, Willumeit-Romer R, Martini F, Mazzoni E, Luthringer-Feyerabend BJC. Slow degrading Mg-based materials induce tumor cell dormancy on an osteosarcoma-fibroblast coculture model. Bioact Mater. 2021 Dec 30;16:320-333. doi: 10.1016/j.bioactmat.2021.12.031. eCollection 2022 Oct. PubMed 35386318 ↗
  • Jaruvongvanich VK, Matar R, Reisenauer J, Janu P, Mavrelis P, Ihde G, Murray M, Singh S, Kolb J, Nguyen NT, Thosani N, Wilson EB, Zarnegar R, Chang K, Canto MI, Abu Dayyeh BK. Hiatal hernia repair with transoral incisionless fundoplication versus Nissen fundoplication for gastroesophageal reflux disease: A retrospective study. Endosc Int Open. 2023 Jan 4;11(1):E11-E18. doi: 10.1055/a-1972-9190. eCollection 2023 Jan. PubMed 36618876 ↗
  • Mattei C, Tricoire-Leignel H, Legros C, Lewis RJ, Molgo J. Editorial: Pharmacological Aspects of Ligand-Gated Ion Channels as Targets of Natural and Synthetic Agents. Front Neurosci. 2022 Apr 8;16:895299. doi: 10.3389/fnins.2022.895299. eCollection 2022. No abstract available. PubMed 35464319 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly. Data will be available only to investigators at participating study centers for the purpose of study coordination, monitoring, and analysis in accordance with the study protocol and applicable data protection regulations. Broader sharing of IPD is not planned due to confidentiality considerations and data use agreements established with participating institutions.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2030, 84 months after the start.

Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 84 months is above that.

Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Feb 9, 2026
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2030
CompletionEst.
Aug 1, 2030
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395219
Lead sponsor
Cleveland Clinic London
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jan 1, 2023
Primary completion
Jan 1, 2030 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion